Amol Akhade/hiranandanihospital.org
May 8, 2025, 16:44
Amol Akhade highlights key trials on neoadjuvant chemotherapy in pancreatic cancer
Amol Akhade, Consultant Medical Oncologist at the Suyog Cancer Clinics, shared on X:
“Neoadjuvant chemo in Pancreatic Cancer: Which trial favors what?
We compared
PANACHE01 (just out in Journal of Clinical Oncology)
SWOG S1505
NORPACT-1
Only NORPACT-1 favored upfront surgery
Others showed feasibility and OS gain with NAC
Checkout both slides below.”
Title: Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study)
Journal: Journal of Clinical Oncology
Authors: Lilian Schwarz, Jean-Baptiste Bachet, Aurelia Meurisse, Olivier Bouché, Eric Assenat, Guillaume Piessen, Pascal Hammel, Nicolas Regenet, Julien Taieb, Olivier Turrini, Francois Paye, Anthony Turpin, Francois-Regis Souche, Christophe Laurent, Reza Kianmanesh, Pierre Michel, Dewi Vernerey, Jean-Yves Mabrut, Celia Turco, Stephanie Truant, Antonio Sa Cunha
Learn more about Amol Akhade on OncoDaily.
Amol Akhade
Anthony Turpin
Antonio Sa Cunha
Aurelia Meurisse
cancer
Celia Turco
Christophe Laurent
Dewi Vernerey
Eric Assenat
Francois Paye
Francois-Regis Souche
Guillaume Piessen
Jean-Baptiste Bachet
Jean-Yves Mabrut
Julien Taieb
Lilian Schwarz
neoadjuvant chemotherapy
Nicolas Regenet
NORPACT-1
Olivier Bouché
Olivier Turrini
OncoDaily
Oncology
PANACHE01
Pancreatic Cancer
Pascal Hammel
Pierre Michel
Reza Kianmanesh
Stephanie Truant
Suyog Cancer Clinics
SWOG S1505
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 29, 2025, 14:15
May 29, 2025, 13:35
May 29, 2025, 13:11
May 29, 2025, 12:46
May 29, 2025, 12:43